Vaccination and Antiviral Treatment of Neglected Diseases Caused by Flaviviral Infections

Autoren

K Schleich
C Nurnberger
A Sobanski
T Efferth

DOI

10.2174/092986711794480168

ISSN

0929-8673

Ausgabe der Veröffentlichung

4

Zeitschrift

Current Medicinal Chemistry

Sprache

en

Paginierung

604 - 614

Datum der Veröffentlichung

2011

Status

Published

Herausgeber

Bentham Science Publishers Ltd.

Herausgeber URL

http://dx.doi.org/10.2174/092986711794480168

Datum der Datenerfassung

2015

Titel

Vaccination and Antiviral Treatment of Neglected Diseases Caused by Flaviviral Infections

Ausgabe der Zeitschrift

18

Data source: Crossref

Abstract

Flaviviral infections have a re-emerging impact on the health situation in developing countries with several billions of people living at risk. In the present review, we focus on three members of the genus Flavivirus belonging to the Flaviviridae family. They are transmitted to humans by mosquito bites, namely those viruses leading to Dengue Fever, Yellow Fever and mosquito-borne Japanese encephalitis. All three virus groups have a spherical structure with a diameter of approximately 50 nm. Although sharing a similar genomic structure and intracellular life cycle, they show different clinical manifestations. Infections are incurable, as there is no antiviral treatment available for either of the three viruses. Thus, prevention and vaccination are the best defenses. The most promising vaccines are live attenuated vaccines (LAVs), such as the YF17D strain against Yellow Fever or the SA-14-14-2 strain against Japanese encephalitis. Additionally, recombinant vaccines for Japanese encephalitis are in development. Although Dengue Fever is the most prevalent arthropode-borne flaviviral infection and a lot of research to develop a vaccine against all four Dengue Fever serotypes was undertaken, no vaccine is available on the market yet. Promising tetravalent vaccine candidates are currently undergoing clinical phase trials, including LAVs, recombinant and chimeric candidates as well as non-replicating vaccine approaches. Additionally, encouraging anti-flaviviral approaches target non-structural proteins, virus-specific proteases essential for cellular maturation of viral particles. Peptide inhibitors against the highly conserved NS2B and NS3 proteases are attractive as pan-flaviviral drug candidates.

Addresses

Institute of Pharmacy and Molecular Biotechnology, University of Heidelberg, Heidelberg, Germany.

Autoren

K Schleich
C Nürnberger
A Sobanski
T Efferth
T Efferth

DOI

10.2174/092986711794480168

eISSN

1875-533X

Externe Identifier

PubMed Identifier: 21143108

Open access

false

ISSN

0929-8673

Ausgabe der Veröffentlichung

4

Zeitschrift

Current medicinal chemistry

Schlüsselwörter

Humans
Dengue
Encephalitis, Japanese
Yellow Fever
Flaviviridae Infections
Recombinant Proteins
Vaccines, Attenuated
Viral Vaccines
Antiviral Agents
Neglected Diseases

Sprache

eng

Medium

Print

Paginierung

604 - 614

Datum der Veröffentlichung

2011

Status

Published

Datum der Datenerfassung

2010

Titel

Vaccination and antiviral treatment of neglected diseases caused by flaviviral infections.

Sub types

Review
Journal Article

Ausgabe der Zeitschrift

18

Data source: Europe PubMed Central

Abstract

Flaviviral infections have a re-emerging impact on the health situation in developing countries with several billions of people living at risk. In the present review, we focus on three members of the genus Flavivirus belonging to the Flaviviridae family. They are transmitted to humans by mosquito bites, namely those viruses leading to Dengue Fever, Yellow Fever and mosquito-borne Japanese encephalitis. All three virus groups have a spherical structure with a diameter of approximately 50 nm. Although sharing a similar genomic structure and intracellular life cycle, they show different clinical manifestations. Infections are incurable, as there is no antiviral treatment available for either of the three viruses. Thus, prevention and vaccination are the best defenses. The most promising vaccines are live attenuated vaccines (LAVs), such as the YF17D strain against Yellow Fever or the SA-14-14-2 strain against Japanese encephalitis. Additionally, recombinant vaccines for Japanese encephalitis are in development. Although Dengue Fever is the most prevalent arthropode-borne flaviviral infection and a lot of research to develop a vaccine against all four Dengue Fever serotypes was undertaken, no vaccine is available on the market yet. Promising tetravalent vaccine candidates are currently undergoing clinical phase trials, including LAVs, recombinant and chimeric candidates as well as non-replicating vaccine approaches. Additionally, encouraging anti-flaviviral approaches target non-structural proteins, virus-specific proteases essential for cellular maturation of viral particles. Peptide inhibitors against the highly conserved NS2B and NS3 proteases are attractive as pan-flaviviral drug candidates.

Date of acceptance

2010

Autoren

K Schleich
C Nürnberger
A Sobanski
T Efferth

Autoren-URL

https://www.ncbi.nlm.nih.gov/pubmed/21143108

DOI

10.2174/092986711794480168

eISSN

1875-533X

Ausgabe der Veröffentlichung

4

Zeitschrift

Curr Med Chem

Schlüsselwörter

Antiviral Agents
Dengue
Encephalitis, Japanese
Flaviviridae Infections
Humans
Neglected Diseases
Recombinant Proteins
Vaccines, Attenuated
Viral Vaccines
Yellow Fever

Sprache

eng

Country

United Arab Emirates

Paginierung

604 - 614

PII

BSP/CMC/E-Pub/2011/ 03

Datum der Veröffentlichung

2011

Status

Published

Datum, an dem der Datensatz öffentlich gemacht wurde

2011

Titel

Vaccination and antiviral treatment of neglected diseases caused by flaviviral infections.

Sub types

Journal Article
Review

Ausgabe der Zeitschrift

18

Data source: PubMed

Vaccination and Antiviral Treatment of Neglected Diseases Caused by Flaviviral Infections

Tools